KR19990009411A - Excellent pharmaceutical composition for the treatment of liver disease - Google Patents

Abstract

The present invention provides a hepatoprotective and hepatic disease treatment agent and a pharmaceutical preparation containing the same, comprising a liver disease treatment agent selected from silymarin, ursodeoxolinic acid (UDCA) and DDB, and an extract of Injinho in a weight ratio of 1: 01-10. To provide, it shows an increased efficacy than when salarimarin, ursodeoxycholic acid, DDB and Injinho, extracts alone.

Description

Excellent pharmaceutical composition for the treatment of liver disease

The present invention relates to a pharmaceutical composition having excellent liver protection and treatment of liver disease. At present, the incidence of liver disease in Korea is considerably higher than that of foreign countries, due to the diet and drinking style. In addition, the target organs of stress chronic fatigue and most exogenous substances that cause various diseases are the liver. However, liver disease is most often found only when symptoms are worse and not asymptomatic or painful in the early stages. Currently, various liver diseases such as hepatitis B, alcoholic fatty liver, and chronic hepatitis caused by hepatitis B virus have emerged as serious social problems. Therefore, the present inventors Injin Ho (Injin, Injin mugwort, heat squid, Korean cognitive, scientific name: artemisia iwayomogi,) and various ratio screening results showed that hepatoprotective and therapeutic effects were much better than when administered alone.

Silymarin, ursodeoxycholic acid (UDCA), DDB, and the like used in the present invention are known to have excellent effects on liver disorders, acute and chronic hepatitis, but their solubility in water is very low. It is low and has many problems to formulate. As a result of animal experiments conducted by the inventors of Injinho, the hepatoprotective effect and the treatment effect against acute hepatitis were observed, and mixed with Injinho extract, silymarin, ursodeoxycholic acid (UDCA), and DDB alone administration. The present invention has been completed by observing that the administration shows better efficacy by synergistic interaction between drugs.

Injinho extract used in the present invention is prepared as follows. After finely cutting Injinho, extract for 4-12 hours with water of 40-100 ℃ and pH 3-9, and repeat extraction 1-2 times under the same conditions. The extract is cooled to room temperature, filtered and the filtrate is concentrated under reduced pressure (water extract: bulk extract). Injinho extract thus prepared and conventional liver disease treatment agents (silymarin, UDCA, DDB) were mixed in various ratios and various soy sauce related drug search was conducted.

Preferred composition of the pharmaceutical composition of the present invention is liver disease treatment agent: Injinho extract = 1: 5-7 parts by weight and the content of silymarin (silymarin), ursodeoxycholic acid (UDCA), DDB 10-50mg, Injinho extract 50-350mg to be.

The pharmaceutical composition of the present invention is preferably mixed with conventional excipients and the like and formulated into a pharmaceutical formulation such as tablets, capsules, solutions, and the like.

It is described in the following experimental example that the pharmaceutical composition of the present invention has excellent hepatoprotective and hepatic disease treatment effects. Injinho extract used in the following experimental example uses the extract of Injinho prepared by the following manufacturing method.

Injinho Extract Preparation Example

After cutting finely 1kg of Injinho, add 5L of water at 80-100 ℃, extract for 5 hours, and extract twice under the same conditions. The extract was cooled to room temperature, filtered, and concentrated under reduced pressure to obtain 30 g of phosphorus extract (water extract: bulk extract).

Experimental Example 1

In order to investigate the hepatoprotective effect of CCl ₄ induced hepatotoxicity in DDB, Injinho extract alone and mixed administration, the following animal experiments were performed. As experimental animals, Sprague-Dawley rats with a body weight of 200g or more were adapted to the animal nursery for constant temperature and humidity for at least one week. Used. The experimental method is as follows. CCl ₄ : corn oil mixture (1: 4 v / v%) intraperitoneally administered 0.2ml per 100g body weight in the rat above 48 hours after open under ether anesthesia and collected in the abdominal aorta and centrifuged Supernatant was taken to measure AST and ALT activity. Each drug of the drug treatment group was suspended in 0.5% CMC solution and administered orally twice 4 hours before and 6 hours after CCl ₄ administration. The experimental results are as follows.

Table 1.

_{4 4 4 4 4 4 4 50 50}

Claims (3)

Hepatic disease treatment with a mixture of hepatic disease selected from silymarin, ursodeoxycholic acid (UDCA), and DDB and Injinho extract In claim 1, the mixing ratio of the liver disease treatment agent and Injinho extract is a liver disease treatment agent, characterized in that the mixing ratio of 1: 1-10. It contains a kind of hepatic disease treatment agent selected from silymarin, ursodeoxycholic acid (UDCA), and DDB and injinhopolysaccharide in a ratio of 0.1 to 10 by weight, and excipients and auxiliaries commonly used pharmaceutically are added thereto A pharmaceutical preparation for hepatoprotective and liver disease treatment prepared by formulating a pharmaceutical formulation in a method commonly used in medicine.